Capital Markets

Goodwin’s unique combination of deep experience serving both the innovators and investors in a rapidly-changing, technology-driven economy sets us apart. We partner with clients to embrace the promise and potential of innovation to make a lasting impact. Our Debt Finance practice represents borrowers, private equity sponsors and lenders in a broad range of financing transactions. Our Debt Finance lawyers work closely with the firm's Private Equity, Technology Companies, Capital Markets, and Financial Restructuring groups structuring, negotiating and documenting domestic and cross-border debt financing arrangements, including secured and unsecured senior, mezzanine and subordinated debt facilities, acquisition-financing transactions, working capital facilities, as well as loan workouts and restructurings.

On the borrower side, Goodwin represents private equity firms and their portfolio companies, leading public and private companies and start-ups in a wide variety of business industries. On the lender side, Goodwin’s clients include domestic and international banks, insurance and finance companies, mezzanine lenders, business development companies and other institutional investors.

Succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. And with the breakneck pace of technology disrupting industries around the world, Goodwin’s depth of experience not only in the life sciences space, but also in collaboration with our technology, healthcare and private equity lawyers, makes our team exceptionally suited to address whatever the future brings. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.

Lawyers in our life sciences practice are deeply experienced in corporate governance, financing and M&A transactions, collaborations and licensing, regulatory matters, and intellectual property law. We understand the challenges of securing funding, safeguarding intellectual property, establishing partnerships, bringing new products to market, opening up new revenue streams, and protecting existing product lines. As part of our interdisciplinary approach, we collaborate with attorneys in our patent litigation, products litigation, employment and tax practices to protect client interests and to advocate on their behalf.

With a full service team of highly experienced lawyers resident in key life sciences hubs, our team helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle. Motivated by the knowledge that the work that we do with you is improving people’s lives, we serve as an extension of your team so you can focus on your core business.

When businesses need counsel at the intersection of real estate and the public markets, they turn to Goodwin, a proven leader and innovator. From the dawn of the REIT market in the 1960s through the modern REIT era that began in the early 1990s, our lawyers are the industry vanguard – helping to draft the Real Estate Investment Trust Act of 1960, pioneering the creation of the first public UPREIT structure, and successfully representing issuers in the largest and most complex REIT IPOs to date. And with the breakneck pace of technology disrupting industries around the world, we partner with our clients and embrace the promise and potential of innovation to make a lasting impact.

Goodwin has been consistently recognized as a leader serving the public REIT market, including in connection with alternative uses of the REIT vehicle, REIT conversions and innovative compensation structures like the modern LTIP partnership unit. As REITs have matured into a mainstream investment with expanded reach around the globe, the industry’s top players continue to rely on our expertise and dedication. And as REITs seek to take advantage of regulatory reforms that broaden their access to capital, such as new exemptions from registration or innovative equity securities, our lawyers are always first on the scene.

When a company is faced with a securities class action or shareholder derivative litigation, they need a partner who understands what is at stake and can think outside the box to achieve resolution. Goodwin’s deep experience, creative thinking and tenacity has led to our involvement in precedent-setting securities cases in courts across the country. The results we achieve are best of breed and have helped shape the law nationally, including outright dismissals of billions of dollars in putative class action and shareholder derivative claims. Our cases range from defending high tech and biotech companies in class action securities fraud litigation brought following restatements of earnings or the release of bad business news, to resolving shareholder derivative challenges, to multibillion dollar mergers and acquisitions.

As a growing technology company, your prospects are exciting and your challenges are unique – from securing funding, protecting IP, and navigating the regulatory environment, to differentiating yourself in the marketplace, managing customer acquisition and scaling your business. We get it. Our dedicated team brings a comprehensive, coordinated approach that interconnects business, new technologies and the law. Our depth of experience in the private equity space along with our technology, healthcare and life sciences lawyers makes Goodwin uniquely suited to harness the breakneck pace of technology. We partner with clients to embrace the promise and potential of innovation to make a profound and lasting impact.